Kiora Pharmaceuticals (KPRX) Research & Development (2014 - 2026)

Kiora Pharmaceuticals (KPRX) has reported Research & Development for 13 consecutive years, with $2.1 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Research & Development fell 19.82% year-over-year to $2.1 million; the trailing twelve-month figure through Jun 2026 stood at $8.7 million (up 7.91% YoY), and the FY2025 full-year result was $10.8 million, up 37.47% from the prior year.
• Research & Development declined to $2.1 million in Q2 2026 per KPRX's latest filing, from $2.1 million in the prior quarter.
• Across five years, Research & Development topped out at $2.7 million in Q3 2025 and bottomed at $438283.0 in Q1 2023.
• Historically, Research & Development has averaged $1.6 million across 5 years, with a median of $1.5 million in 2023.
• The sharpest annual moves came in 2022 and 2024: Research & Development sank 60.61% in 2022, then surged 284.28% in 2024.
• Over 5 years, Research & Development stood at $841617.0 in 2022, then soared by 32.08% to $1.1 million in 2023, then tumbled by 33.47% to $739557.0 in 2024, then jumped by 136.98% to $1.8 million in 2025, then advanced by 18.52% to $2.1 million in 2026.
• According to Business Quant data, Research & Development over the past three periods registered $2.1 million, $2.1 million, and $1.8 million for Q2 2026, Q1 2026, and Q4 2025 respectively.